Epinephrine: Difference between revisions
No edit summary |
|||
| Line 20: | Line 20: | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
''See [[critical care quick reference]] for drug doses by weight.'' | ''See [[critical care quick reference]] for drug doses by weight.'' | ||
==Pressors== | |||
===Dosing=== | |||
*Dose-dependent effects: | |||
*1-10 mcg/min - increase HR and SV | |||
*10-20 mcg/min - increase SVR | |||
===Rate of Titration=== | |||
*Q2-5 min | |||
==Special Populations== | ==Special Populations== | ||
| Line 54: | Line 62: | ||
*↑↑↑SVR | *↑↑↑SVR | ||
*Bronchodilation (β2) | *Bronchodilation (β2) | ||
==Notes== | |||
*↑lactate occurs primarily from ↑glycolysis/glycogenolysis within skeletal muscles not tissue hypoperfusion | |||
*Use with caution in pts with CAD | |||
**However clinical trials have not demonstrated worsened outcomes | |||
==See Also== | ==See Also== | ||
| Line 63: | Line 76: | ||
<references/> | <references/> | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Revision as of 14:39, 20 December 2014
General
- Type: Vasopressors
- Dosage Forms:
- Concentration
- Amount of solution in mL used to dilute 1,000mg of epinephrine
- eg 1:10,000 = 1,000mg/10,000mL = 0.1mg/mL
- Common Trade Names: Adrenaline
Adult Dosing
Anaphylaxis
0.3-0.5mg of 1:1,000 IM
- Consider glucagon 1-5mg IV if pt on B-blockers and not responding to epi
Anaphylactic shock
0.1mg of 1:10,000 slow IV during 5 min, can start infusion of 1-4 mcg/min
Cardiac Arrest
1mg of 1:10,000 IVP
Pediatric Dosing
See critical care quick reference for drug doses by weight.
Pressors
Dosing
- Dose-dependent effects:
- 1-10 mcg/min - increase HR and SV
- 10-20 mcg/min - increase SVR
Rate of Titration
- Q2-5 min
Special Populations
- Pregnancy Rating:
- Lactation:
- Renal Dosing
- Adult
- Pediatric
- Hepatic Dosing
- Adult
- Pediatric
Contraindications
- Allergy to class/drug
Adverse Reactions
- Tachyarrhythmias
- Myocardial ischemia
- ↑Serum lactate
- Splanchnic ischemia
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
- Mechanism of Action:
Primary Receptor
- β1
- α1
- β2
Relative Effects
- ↑↑↑HR
- ↑↑↑SV
- ↑↑↑SVR
- Bronchodilation (β2)
Notes
- ↑lactate occurs primarily from ↑glycolysis/glycogenolysis within skeletal muscles not tissue hypoperfusion
- Use with caution in pts with CAD
- However clinical trials have not demonstrated worsened outcomes
